Advances in atopic dermatitis and urticarial in 2016

Area of Science:

• Dermatology
• Immunology
• Microbiology

Background:

• Atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) are significant inflammatory skin diseases with complex etiologies.
• Understanding the underlying pathology and identifying novel therapeutic targets are crucial for improving patient outcomes.

Purpose of the Study:

• To review recent advancements in the pathology and therapies of atopic dermatitis (AD) and chronic spontaneous urticaria (CSU).
• To highlight novel insights into immune profiles, skin microbiome dysbiosis, and potential therapeutic strategies for AD and CSU.

Main Methods:

• Transcriptomic analysis of human samples for AD immune profiling.
• Review of Phase III clinical trials for dupilumab (anti-IL-4 receptor α antibody) in AD.
• Evaluation of Phase II trial results for an IL-31 targeting biologic.
• Analysis of studies investigating skin microbiome alterations in AD.
• Discovery of autoreactive CD4+ T cells targeting FcεRI in CSU.

Main Results:

• Distinct immune profiles identified between childhood and adult atopic dermatitis.
• Dupilumab, a biologic targeting the IL-4 receptor α, demonstrates efficacy in AD treatment.
• A novel biologic targeting IL-31 shows promising results in Phase II trials for AD.
• New insights into Staphylococcus aureus colonization and microbial dysbiosis in AD pathogenesis.
• Identification of autoreactive CD4+ T cells implicated in the development of CSU.

Conclusions:

• Recent findings offer deeper understanding of AD and CSU pathogenesis.
• Novel therapeutic targets, including biologics, are emerging for AD and CSU.
• These advancements pave the way for more personalized and specific treatments for inflammatory skin diseases.